Category: Oncology

Greetings, dear readers! Today, let’s delve into the exciting realm of oncology and explore the groundbreaking first-in-human data supporting the use of Izalontamab in the treatment of advanced epithelial tumors. This novel therapeutic agent has been making waves in the biopharmaceutical industry, offering new hope to patients facing these challenging malignancies. Unraveling the Enigma of […]

The recent FDA fast-track approval of AVZO-1418, a bispecific antibody-drug conjugate (ADC), for the treatment of EGFR-mutated pretreated non-small cell lung cancer (NSCLC) has sparked excitement in the biotech community. This groundbreaking decision marks a significant milestone in the realm of precision medicine, offering new hope for patients with advanced NSCLC who have previously undergone […]

Greetings and salutations, dear readers! Today, let’s embark on a whimsical journey through the captivating realm of precision medicine and the enthralling fusion of multiomics and artificial intelligence in the context of localized Non-Small Cell Lung Cancer (NSCLC). Imagine a world where cutting-edge technology intertwines with the intricate web of biological data to unlock the […]

Precision oncology, a groundbreaking approach in cancer treatment, is rapidly advancing with the integration of ex vivo technology. This innovative method involves extracting cancer cells from a patient, cultivating them in a controlled environment outside the body, and subjecting them to various treatments to determine the most effective therapy. By utilizing ex vivo technology, oncologists […]

Greetings, esteemed readers. Today, we delve into the intricate realm of precision oncology, specifically focusing on the contrasting therapeutic landscapes of Osimertinib and Amivantamab-Lazertinib in the frontline treatment of EGFR-mutated Non-Small Cell Lung Cancer (NSCLC). Guided by the profound insights of Dr. Danny Nguyen, a luminary in the field of oncology, we embark on a […]

In the dynamic landscape of biotechnology, the intersection of innovation and patient care is witnessing groundbreaking advances in outpatient treatment modalities, particularly in the realm of Bispecific Antibodies and Antibody-Drug Conjugates (ADCs). Renowned expert Scott Soefje, PharmD, MBA, BCOP, sheds light on the transformative potential of these therapeutic modalities in reshaping the delivery of care […]

In a groundbreaking development, the FDA has granted its stamp of approval for Jobevne, a biosimilar of the well-known drug Avastin. This significant milestone opens up new avenues in the treatment landscape for various types of cancer, heralding a new era of possibilities for patients and healthcare providers alike. Let us delve into the intricacies […]

Oh, the dance of power and desperation in the pharmaceutical realm! Mytesi, a potential game-changer in the realm of treating diarrhea in breast cancer patients, is now making its bold move towards obtaining the coveted FDA Orphan Drug Designation. This designation, a golden ticket in the pharmaceutical world, could open doors and pave the way […]

In the fast-evolving landscape of oncology research, the integration of multi-omics data has emerged as a potent tool for unraveling the complexities of cancer biology. By combining genomics, transcriptomics, proteomics, and metabolomics data, researchers can gain a holistic understanding of the molecular mechanisms driving tumorigenesis and identify novel therapeutic targets. This approach not only provides […]

Step into the realm of oncology, where every pulse of innovation resonates with hope and promise for those battling against the relentless grip of cancer. The symphony of breakthroughs and FDA approvals orchestrates a narrative of resilience and progress, offering a lifeline to patients and clinicians navigating the complex landscape of targeted therapies and clinical […]

In the ever-evolving landscape of lung cancer research, the spotlight has long been on EGFR mutations, which play a pivotal role in driving the disease. For over two decades, the focus has primarily been on the more common “classical” mutations, such as the exon 19 deletion or the L858R mutation. However, with advancements in diagnostic […]

Welcome, dear readers, to a fascinating journey into the realm of cutting-edge oncology. Today, we delve into the groundbreaking results of the phase 3 INSPIRE study, where a new hero emerges in the fight against ALK-positive non-small cell lung cancer (NSCLC) – Iruplinalkib. In a stunning revelation, the INSPIRE study unveiled that Iruplinalkib, a next-generation […]

The FDA’s recent approval of Bosaya and Aukelso marks a significant milestone in the treatment of solid tumors such as breast and prostate cancer. These biosimilars, developed by Biocon Biologics Ltd., are designed to provide a more affordable option for patients at high risk of fractures undergoing cancer therapies. Bosaya and Aukelso, biosimilars of Prolia […]

Noninvasive biomarkers play a pivotal role in the realm of precision oncology, offering valuable insights into disease progression, treatment efficacy, and patient outcomes. These biomarkers, sourced from liquid biopsies and advanced imaging techniques, hold immense potential in shaping personalized cancer care. However, their effective validation and application differ significantly between real-world data (RWD) and clinical […]

AI is revolutionizing the field of oncology, yet clinicians often lack the necessary tools to assess the reliability of AI models in real-world scenarios. A recent study introduces a novel checklist and questionnaire specifically designed for clinicians to evaluate artificial intelligence and machine learning models in cancer care settings. Traditional guidelines are typically geared towards […]

In a groundbreaking move, the U.S. Food and Drug Administration (FDA) has recently bestowed breakthrough therapy designation upon Raludotatug Deruxtecan (R-DXd) for adults grappling with CDH6-expressing platinum-resistant ovarian, peritoneal, or fallopian tube cancers. This monumental decision marks a pivotal juncture in the realm of oncology, offering a ray of hope for patients confronting the harsh […]

In the realm of oncology, a burgeoning landscape of almost 50 novel cancer treatments emerges annually, a beacon of hope for patients battling this relentless disease. However, amidst this promising surge, the challenge lies in deciphering the optimal treatment modalities tailored to the unique tumor characteristics of each individual. Altuna Akalin, the ingenious mind spearheading […]

In the realm of high-grade ovarian cancer treatment, a notable portion of patients—approximately 20%—fail to respond to standard chemotherapy regimens. Deciphering which individuals will benefit from these treatments has long posed a significant challenge in the field. However, recent advancements in the form of an ex vivo 3D micro-tumour testing platform are paving the way […]

The recent approval by the FDA of selumetinib for the treatment of pediatric patients aged 1 year and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN) marks a significant milestone in pediatric oncology. This approval offers new hope for young patients facing these challenging conditions, providing a much-needed treatment option where […]

In the realm of oncology, especially in the treatment landscape of metastatic breast cancer, biosimilars have been gaining traction for their potential to enhance treatment access and affordability. A notable contender in this space is HLX02, a trastuzumab biosimilar showing promise in providing safe and effective treatment for HER2-positive metastatic breast cancer patients. Real-world evidence […]

Introduction: In a groundbreaking move, the Food and Drug Administration has given its stamp of approval to a novel drug-device combination developed by Johnson & Johnson for the treatment of bladder cancer. This innovative approach, named Inlexzo, marks a significant advancement in the field of oncology, offering new hope to patients who have exhausted traditional […]

Onco-Innovations Limited, represented by its subsidiary Inka Health Corp., is set to take the helm at the upcoming roundtable organized by Colorectal Cancer Canada (CRC), focusing on data innovation and digital trust in oncology. This significant leadership role underscores Onco-Innovations’ increasing involvement in shaping national dialogues that are pivotal to the advancement of cancer care […]

In the realm of oncology drug development, the escalating costs of innovative cancer therapies have become a focal point of discussion, prompting the call for enhanced collaboration, data sharing, and the implementation of value-based care models. At the recent PBMI annual meeting, industry experts underscored the imperative for greater transparency, precision medicine adoption, and the […]

Eli Lilly’s groundbreaking blood cancer drug Jaypirca (pirtobrutinib) is poised for accelerated growth with promising results from the BRUIN CLL-313 trial, indicating its potential to transition into the frontline treatment setting for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This reversible BTK inhibitor has demonstrated a significant improvement in progression-free survival compared to […]

In the realm of oncology, where each scientific advancement brings hope and promise, a recent milestone has been achieved in the fight against glioblastoma. The FDA’s decision to grant orphan drug designation to BA-101, an investigational therapy, marks a significant step forward in addressing the urgent unmet medical needs of patients battling this aggressive form […]

Greetings, fellow science enthusiasts! Today, we embark on a thrilling journey into the realm of innovative oncology as we delve into the groundbreaking acquisition of HistoSonics, a company at the forefront of noninvasive liver cancer treatment. This transformative milestone not only signifies a monumental leap in the evolution of focused ultrasound technology but also opens […]

The recent approval by the Food and Drug Administration (FDA) of Johnson & Johnson’s (J&J) drug-device combination for bladder cancer marks a significant milestone in the field of oncology. This innovative therapy, now known as Inlexzo, offers a novel approach to treating bladder cancer, potentially revolutionizing current practices. Developed by J&J, Inlexzo combines a medical […]

ShinlaGen has embarked on an innovative journey in the field of immuno-oncology with its groundbreaking GEEV platform. This next-generation oncolytic virus therapy technology is set to revolutionize cancer treatment by allowing oncolytic viruses to be administered intravenously, evading immune system attacks and providing systemic anti-cancer effects. The GEEV platform developed by ShinlaGen represents a significant […]

Karyopharm Therapeutics Inc., a leading commercial-stage pharmaceutical company specializing in innovative cancer treatments, has achieved a significant milestone by completing enrollment in the phase 3 SENTRY trial. This trial focuses on evaluating the efficacy of selinexor in combination with ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. The completion of enrollment marks a crucial step towards […]

MedGenome has introduced the CNS Tumor Methylation Classifier Test, a pioneering diagnostic tool in India capable of distinguishing and categorizing more than 90 types of brain and central nervous system (CNS) tumors into precise subtypes. This cutting-edge test provides valuable insights for doctors to make informed treatment decisions. Unveiled at a precision oncology symposium in […]

The FDA has recently bestowed breakthrough device designation upon the Haystack MRD test, a circulating tumor DNA (ctDNA) assay developed by Quest Diagnostics, for its potential utility in patients with stage II colorectal cancer post-surgery. This designation acknowledges the test’s ability to enhance the management of minimal residual disease (MRD) in this patient population, aiding […]

A recent study published in JAMA Surgery has unveiled the potential of Destinex, an exosome-based liquid biopsy assay, in accurately detecting gastric cancer (GC) at an early stage. Led by Silei Sui from the Department of Molecular Diagnostics and Experimental Therapeutics at the Beckman Research Institute of City of Hope in California, the research focused […]

Eli Lilly and Company recently shared an update on their ongoing clinical trial investigating a potential game-changing cancer therapy. The study, titled “A Phase 1a/b Multicenter, Open-Label Trial to Evaluate Safety, Tolerability, and Dosimetry of LY4257496,” focuses on assessing the safety, tolerability, and efficacy of LY4257496, a GRPR-Targeted Radioligand Therapy, in adults with GRPR-positive advanced […]

The biosimilars market, as analyzed by DataM Intelligence, exhibited a noteworthy valuation of US$ 22.58 billion in 2024. Projections indicate a substantial increase to US$ 171.79 billion by 2033, with a compound annual growth rate (CAGR) of 25.5% during 2025–2033. This growth trajectory is attributed to factors such as increasing regulatory approvals, expiring patents of […]

Clayton Irvine, a distinguished professional with a PharmD, MBA, MS background, advocates for the strategic utilization of high-quality real-world data and collaborative efforts between academic and community healthcare entities to enhance oncology care. He stresses the significance of standardized care pathways, advanced technologies, and integrated partnerships to streamline treatment decisions, mitigate financial challenges, address drug […]

In the realm of oncology, the integration of artificial intelligence (AI) into medical imaging has revolutionized how we perceive and treat cancer. Gone are the days of static imaging; AI now plays a dynamic role in supporting early therapy decisions, facilitating clinical trial recruitment, personalizing patient care, and monitoring treatment effectiveness in real-time. By classifying […]

Dr. Nikhita Kathuria-Prakash, an Indian American medical oncologist and hematologist, has recently become a part of the Florida Cancer Specialists & Research Institute (FCS) located in Lake City, Florida. Her expertise spans across clinical care, research, teaching, and initiatives to enhance the delivery of oncology care. Dr. Kathuria-Prakash’s dedication to medical education and community outreach […]

Ipsen, a leading French pharmaceutical company, has recently announced significant changes to its executive committee. Mari Scheiffele, a seasoned professional with a proven track record in commercial operations, is appointed as the new executive vice president and chief product officer. She will spearhead the development of innovative medicines in oncology and rare diseases, focusing on […]

French pharmaceutical company Ipsen has achieved a significant milestone with the European Commission’s approval of Cabometyx (cabozantinib) for adult patients with unresectable or metastatic, well-differentiated pancreatic (pNET) and extra-pancreatic (epNET) neuroendocrine tumors who have not responded to previous systemic therapy. Originally developed by Exelixis, Ipsen now holds exclusive rights for commercialization and further clinical development […]

Lantern Pharma Inc. (NASDAQ: LTRN) has recently appointed Dr. Lee T. Schalop, MD, a seasoned biotech executive and Wall Street analyst, to its Board of Directors. Dr. Schalop’s extensive experience in biotechnology leadership and financial markets, particularly in precision neurooncology and clinical development, makes him a valuable addition to Lantern Pharma’s team. With a successful […]

In the realm of early-stage TNBC treatment, the PD-1 inhibitor KEYTRUDA (pembrolizumab) has emerged as a pivotal component. Administered in conjunction with neoadjuvant chemotherapy and continued as adjuvant monotherapy, KEYTRUDA has showcased promising results. Particularly in PD-L1-positive patients with a CPS ≥10, it is utilized alongside chemotherapy for locally recurrent or metastatic disease. The landscape […]

The treatment landscape for EGFR-mutated NSCLC is rapidly evolving, offering a diverse array of therapeutic choices that can be strategically integrated into a patient’s treatment journey. With the recent FDA approval of Dato-DXd, there is a new therapeutic avenue for patients who have previously received EGFR-directed therapy and chemotherapy. This expansion in treatment options introduces […]

The IMpassion031 trial, incorporating atezolizumab alongside neoadjuvant chemotherapy, has showcased remarkable long-term outcomes in patients with stage II/III triple-negative breast cancer (TNBC). With approximately 3 years of follow-up data, the final analysis of this phase 3 trial not only confirms the initial success in enhancing pathologic complete response (pCR) rates but also delves into the […]

Bevacizumab, a vital medication in the treatment of recurrent glioblastoma, has shown promise in extending progression-free survival and enhancing quality of life for patients. However, determining which patients would benefit most from this drug has been a challenge – until now. According to a groundbreaking study by the University of Kentucky’s Markey Cancer Center, researchers […]

Recent advancements in breast cancer vaccine research have sparked hope for preventing and treating this prevalent disease. One notable trial focuses on developing a vaccine targeting the alpha-lactalbumin protein found in triple-negative breast cancer (TNBC) cases. This innovative approach aims to stimulate the immune system to attack TNBC tumors and inhibit their growth. If successful, […]

As immune cell effector therapies like CAR T-cell and bispecific T-cell engagers become more prevalent in cancer treatment, it is crucial for nurses and advanced practice providers (APPs) to understand the potential adverse effects (AEs) associated with these innovative therapies. Experts from the 2025 Immune Cell Effector Therapies (ICE-T) Conference shed light on the importance […]

Delving into the complex case of a 60-year-old man battling primary refractory diffuse large B-cell lymphoma (DLBCL), this in-depth analysis sheds light on the therapeutic hurdles faced in such scenarios. Despite undergoing standard frontline treatment with R-CHOP, the patient encountered early disease progression within a mere 7 months, indicating chemo-refractory disease with a grim prognosis. […]

Autocrine signaling plays a pivotal role in the development and progression of cancer by promoting self-stimulation in cancer cells through the production and reception of signaling molecules. Faulty regulations of autocrine signaling can transform healthy cells into cancer cells, initiating tumor growth and contributing to metastasis and therapy resistance. This blog post explores the significance […]

Immutep Limited is paving the way for innovative cancer treatment with their proprietary soluble LAG-3 protein and MHC Class II agonist, Eftilagimod Alfa (efti). Efti stimulates both innate and adaptive immunity, activating a range of immune cells crucial for fighting cancer. This first-in-class antigen presenting cell (APC) activator has shown promise in the treatment of […]

Recent research has unveiled a groundbreaking approach to treating low-grade, intermediate-risk, non–muscle-invasive bladder cancer (LG-IR-NMIBC) patients. The exploration of home-based mitomycin instillation, facilitated by UroGen Pharma’s innovative RTGel® technology, has shown significant promise in enhancing patient access to care and improving treatment efficiency. This transformative shift towards patient-centric care delivery not only empowers individuals with […]

Bladder cancer treatment may be on the brink of a revolutionary transformation, thanks to a groundbreaking biomimetic drug delivery platform inspired by gecko feet. Soft dendritic particles (SDPs) offer a promising solution to the challenges of poor drug retention and limited therapeutic effectiveness in intravesical drug delivery. Coated with chitosan for enhanced adherence to bladder […]

In a bold move that signifies a significant advancement in the oncological landscape, Viz.ai has announced a strategic partnership with pharmaceutical giant Novartis. This alliance leverages the power of artificial intelligence (AI) to transform the way cancer care is delivered, promising to expedite diagnosis and precision care for prostate and breast cancer patients. This alliance […]

The US Food and Drug Administration (FDA) has approved darolutamide (Nubeqa), setting a new precedent in the realm of metastatic castration-sensitive prostate cancer (mCSPC) treatment. Produced by Bayer Healthcare Pharmaceuticals, darolutamide’s approval heralds a promising era of treatment options that extend beyond the traditional confines of androgen deprivation therapy (ADT). This approval was anchored by […]

Investors are closely monitoring the performance of Verastem Oncology stock this Monday. Analysts are paying attention to various technical indicators, such as the 200-day moving average, to gauge the stock’s potential future trend. Currently, the stock price is above the 200-day moving average, indicating a bullish signal. To learn more about how technical analysis tools […]

Exciting news for the Oncology Institute as they are set to join the prestigious Russell 2000 and Russell 3000 Indexes. The annual reconstitution of the Russell indexes has identified the 4,000 largest US stocks as of April 30, ranking them based on total market capitalization. Membership in the US all-cap Russell 3000 Index guarantees automatic […]